Latest Eisai Co Ltd (ESALF) Headlines
Arterial Thrombosis - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 24, 3:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/f8f4ch/arterial) has announced the addition of the "Arterial Thrombosis - Pipeline Review, H2 2013" report to their offering. 'Arterial Thrombosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Arterial Thrombosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Arterial Thrombosis. Scope - A snapshot of the global therapeutic scenario for Arterial Thrombosis. - A review of the Arterial Thrombosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Arterial Thrombosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Arterial Thrombosis Overview Therapeutics Development Pipeline Products for Arterial Thrombosis - Overview Late Stage Products Clinical Stage Products Early Stage Products Arterial Thrombosis - Products under Development by Companies Arterial Thrombosis - Therapeutics Assessment Drug Profiles ticagrelor - Drug Profile temanogrel hydrochloride - Drug Profile PZ-128 - Drug Profile BMS-593214 - Drug Profile ER-410660 - Drug Profile E-5539 - Drug Profile Arterial Thrombosis - Recent Pipeline Updates Arterial Thrombosis - Dormant Projects Arterial Thrombosis - Product Development Milestones Featured News & Press Releases List of Tables List of Figures Companies Mentioned Bristol-Myers Squibb Company AstraZeneca PLC Eisai Co., Ltd. Arena Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/f8f4ch/arterial About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Advisory: Public Health Agency of Canada
Marketwire - Fri Feb 21, 2:35PM CST
The Honourable Rona Ambrose, Federal Minister of Health, joined by Canadian Tire and LIFT Philanthropy Partners, will announce an important initiative to encourage children and youth and all Canadians to be more active.
Access Midstream Partners Posts Financial Results for the 2013 Fourth Quarter and Full Year
Close-Up Media - Thu Feb 20, 11:31PM CST
Access Midstream Partners, L.P. announced financial results for the 2013 fourth quarter and full year. The Partnership's adjusted EBITDA for the 2013 fourth quarter totaled $240.6 million, an increase of $121.6 million, or 102.2 percent, from 2012 fourth quarter adjusted EBITDA of $119.0 million.
Global Amyotrophic Lateral Sclerosis Market 2014-2018: Advanced New Discoveries and Treatments Sheds Light on Factors Involved In ALS
M2 - Thu Feb 13, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/3qv6rf/global) has announced the addition of the "Global Amyotrophic Lateral Sclerosis Market 2014-2018" report to their offering. The analysts forecast the Global Amyotrophic Lateral Sclerosis Drugs Market to grow at a CAGR of 5.39 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Amyotrophic Lateral Sclerosis Drugs Market has also been witnessing the increasing awareness of ALS drugs. However, the patent expiry of Rilutek could pose a challenge to the growth of this market. Key vendors dominating this space include Covis Pharmaceutical Inc., Eisai Co. Ltd., GlaxoSmithKline plc, and Mitsubishi Tanabe Pharma Corp. Other vendors mentioned in the report are Amorfix Life Sciences Ltd., BrainStrom Cell Therapeutics Inc., Newron Pharmaceuticals S.p.A, Neuraltus Pharmaceuticals Inc., Nutra Pharma Corp., Oxford BioMedica plc, Pharnext SAS, and Q-Therapeutics Inc. Commenting on the report, an analyst from the team said: The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as ALS awareness month. The ALS Association strives to involve and engage patients and families in the process of increasing awareness and advocating for legislative changes. Similarly, CDMRP also organizes the ALS Research Program. The global research effort through this program has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS. According to the report, one of the main drivers in this market is the increase in the aging population. The number of patients suffering from ALS is increasing due to its relatively high prevalence in the elderly population. For more information visit http://www.researchandmarkets.com/research/3qv6rf/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013
M2 - Thu Feb 13, 2:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/dcl2zl/recurrent) has announced the addition of the "Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013" report to their offering. 'Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM). Key Topics Covered: Introduction Recurrent Glioblastoma Multiforme (GBM) Overview Therapeutics Development Clinical Stage Products Early Stage Products Drug Profiles bosutinib - Drug Profile axitinib - Drug Profile onartuzumab - Drug Profile dacomitinib - Drug Profile rindopepimut - Drug Profile VB-111 - Drug Profile ANG-1005 - Drug Profile AT-101 - Drug Profile vorinostat - Drug Profile buparlisib hydrochloride - Drug Profile pazopanib hydrochloride - Drug Profile memantine hydrochloride - Drug Profile galunisertib - Drug Profile G-200 - Drug Profile ERC-1671 - Drug Profile lenvatinib - Drug Profile trebananib - Drug Profile TB-403 - Drug Profile nabiximols - Drug Profile golvatinib - Drug Profile ARC-100 - Drug Profile New Castle Disease Virus - HUJ Oncolytic Virus - Drug Profile vocimagene amiretrorepvec flucytosine ER - Drug Profile golvatinib lenvatinib - Drug Profile ICT-121 - Drug Profile BTSC mRNA Loaded Dendritic Cell Vaccine - Drug Profile AZD-7451 - Drug Profile DNX-2401 - Drug Profile OS-2966 - Drug Profile Recurrent Glioblastoma Multiforme (GBM) - Recent Pipeline Updates Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects Recurrent Glioblastoma Multiforme (GBM) - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned F. Hoffmann-La Roche Ltd. Amgen Inc. AstraZeneca PLC Eli Lilly and Company GlaxoSmithKline plc Agenus, Inc. Merck & Co., Inc. Novartis AG Eisai Co., Ltd. Pfizer Inc. GW Pharmaceuticals plc Celldex Therapeutics, Inc. ImmunoCellular Therapeutics, Ltd. ThromboGenics NV AngioChem Inc. Ascenta Therapeutics, Inc. Vascular Biogenics Ltd. Archer Biosciences, Inc Tocagen Inc. DNAtrix, Inc. ERC Belgium SA OncoSynergy Inc For more information visit http://www.researchandmarkets.com/research/dcl2zl/recurrent About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Eisai Announces Launch of Pariet(R) Triple Formulation Combination Packs Rabecure(R) 400 and 800 and Rabefine(R), for Primary and Secondary H.Pyloei Eradication Respectively, in Japan
JCN Newswire - Wed Feb 12, 11:09PM CST
Eisai Co., Ltd. announced today that it will launch two types of triple formulation combination packs that contain its proton pump inhibitor Pariet(R) (rabeprazole sodium) in Japan on February 14 for use in Helicobacter pylori eradication.
Eisai Announces Launch of Vascular Embolization Device DC Bead(R) in Japan
JCN Newswire - Mon Feb 03, 1:19AM CST
Eisai Co., Ltd. announced today that it will launch the vascular embolization device DC Bead(R) (specially controlled medical device) in Japan on February 4.
Phase III Trial Shows Lenvatinib Meets Primary Endpoint of Progression Free Survival Benefit in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
JCN Newswire - Mon Feb 03, 1:18AM CST
Eisai Co., Ltd. announced today that the Phase III SELECT trial (Study 303) of lenvatinib, an investigational selective tyrosine kinase inhibitor (TKI) with a novel binding mode, the first-in-class of its kind, met its primary endpoint. Compared to placebo, lenvatinib showed a highly statistically significant improvement in progression free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC).
Latest Thyroid Cancer Pipeline Review
M2 - Tue Jan 28, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/zmc3df/thyroid_cancer) has announced the addition of the "Thyroid Cancer - Pipeline Review, H2 2013" report to their offering. 'Thyroid Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer. Scope - A snapshot of the global therapeutic scenario for Thyroid Cancer. - A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Thyroid Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Bio-Path Holdings, Inc. - Eisai Co., Ltd. - Bayer AG - Bionomics Limited - Azaya Therapeutics Incorporated - Vascular Biogenics Ltd. - Biovista Inc. - Trophogen, Inc. - centrose llc - Ecrins Therapeutics SAS For more information visit http://www.researchandmarkets.com/research/zm...oid_cancer
Fashion - How to Wear Leggings
by Shifa Mwesigye - All Africa Global Media - Tue Jan 21, 11:31PM CST
Ladies, legging are not pants, they should not be won with a tank top, however well your behind may be rounded. Even if you have the perfect hour-glass figure, you have to cover it up - I mean the butt.
Venous Thromboembolism Global Clinical Trials Review, H2 2013 Report
M2 - Fri Jan 17, 9:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/t9vr95/venous) has announced the addition of the "Venous Thromboembolism Global Clinical Trials Review, H2, 2013" report to their offering. Venous Thromboembolism Global Clinical Trials Review, H2, 2013 provides data on the Venous Thromboembolism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Venous Thromboembolism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Venous Thromboembolism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Venous Thromboembolism Therapeutics Clinical Trials - Bayer AG - Sanofi - GlaxoSmithKline plc - C. H. Boehringer Sohn AG & Co. KG - Astellas Pharma Inc. - Daiichi Sankyo Company, Limited - Pfizer Inc. - AstraZeneca PLC - Bristol-Myers Squibb Company - Eisai Co., Ltd. Clinical Trial Overview of Top Institutes / Government - National Heart, Lung, and Blood Institute - Hamilton Health Sciences - Ottawa Hospital Research Institute - Brigham and Women's Hospital - McMaster University - Centre Hospitalier Universitaire de Saint Etienne - Universita di Padova - Mayo Clinic - Universita degli Studi dell'Insubria - The Utrecht Institute for Pharmaceutical Sciences For more information visit http://www.researchandmarkets.com/research/t9vr95/venous
MCB Bank Selects Oracle WebLogic Suite 12c to Support Its Core Banking Upgrade to Power Exceptional Experiences for Employees and Customers
M2 - Thu Jan 16, 9:29AM CST
News Summary
Sezary Syndrome Global Clinical Trials Review, H2 2013 - Features Players such as Merck & Co., Inc. and Shionogi & Co., Ltd.
M2 - Fri Jan 10, 3:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/l3xgrw/sezary_syndrome) has announced the addition of the "Sezary Syndrome Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Sezary Syndrome Global Clinical Trials Review, H2, 2013" provides data on the Sezary Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sezary Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sezary Syndrome. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: -Angimmune LLC -Eisai Co., Ltd. -Emergent BioSolutions Inc. -Janssen Global Services, LLC -Kirin Holdings Company, Limited -Merck & Co., Inc. -National Cancer Institute -Northwestern University -OncoSec Medical Inc. -Roswell Park Cancer Institute -Shionogi & Co., Ltd. -Spectrum Pharmaceuticals, Inc. -Stanford University -University of Washington -Wake Forest University For more information visit http://www.researchandmarkets.com/research/l3...y_syndrome About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Pharmerging Market Report - Forecasts to 2016
M2 - Thu Jan 09, 10:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/w9jhsf/pharmerging) has announced the addition of the "Global Pharmerging Market Report - Forecasts to 2016" report to their offering. One of the major drivers in this market is the increased healthcare spending. It was estimated that Pharmerging markets constitute about 20 percent of pharmaceutical spending and are expected to contribute 30 percent by 2016 of the Global Pharmaceutical market spending. Partnership activities with vendors toward the development of new products especially generic drugs are increasingly being adopted by big pharmaceutical companies to sustain their presence in the Pharmerging markets. For example, Pfizer Inc. announced a partnership with Laborat?rio Teuto Brasileiro SA to develop and commercialize generic medicines in 2010. Another example includes Eli Lilly which expanded a strategic partnership with Chinese manufacturer Novast Laboratories Ltd. in 2011 to serve Chinese patients with high-quality generic medicines. Such partnership activities are expected to grow during the forecast period, boosting the Pharmerging markets. Further, the report states that one of the challenges in this market is the price pressure faced by the big pharmaceutical companies. Governments in the Pharmerging markets have developed policies that favor the local manufacturers. In order to market their products big pharmaceutical companies are forced to reduce their product prices to attract the local populace and government. The key vendors dominating this market space are: - Abbott Laboratories - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca plc. - Bayer HealthCare AG. - Boehringer Ingelheim Pharmaceuticals Corp. - Bristol-Myers Squibb Co. - Eisai Co Ltd. - GlaxoSmithKline plc - Johnson & Johnson - Eli Lilly and Co. - Merck & Co Inc. Novartis International AG. - Novo Nordisk A/S. - Pfizer Inc. - Roche Holding Ltd. - Sanofi S.A. Key Topics Covered: 01. Executive Summary 02. Scope of the Report 03. Market Research Methodology 04. List of Abbreviations 05. Introduction 06. Market Landscape 07. Market Segmentation by Geographical Regions 08. Market Overview of Tier 1 Countries 09. Market Overview of Tier 2 Countries 10. Tier 3 Countries 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/w9...harmerging
2013 Report on the International Epigenetics Technology Market - World Forecasts to 2017
M2 - Mon Jan 06, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/27bx7t/epigenetics) has announced the addition of the "2013 Report on the International Epigenetics Technology Market - World Forecasts to 2017" report to their offering. This technology report categorizes the market for epigenetics by geographical region (including the important countries in each region), applications, and epigenetic mechanisms, forecasting the market value in revenue by analyzing the current and future trends in research, diagnostics and therapeutics industries. A detailed description of the global technology developments and evolving trends in the epigenetics field with key prominence on research innovations, collaborative efforts and focused research through consortiums dedicated for epigenetics. A close view on the drug development for treatment of various diseases by providing the details and status of current epigenetic drugs in pipeline. An impact analysis of major drivers, restraints and challenges influencing the adoption and growth of epigenetics market during the period from 2012 to 2017. Market size - Global market forecast for 2012-2017, including demand side analysis and strategic recommendations for technology/product developers. Competitive landscape based on the analysis of key patents and research publications that gives an insight into prominent activities and global participants. Key Topics Covered: 1. Introduction 2. Executive Summary 3. Epigenetics - Technology Landscape Analysis 4. Epigenetics - Market Landscape Analysis 5. Technology Investment Potential 6. Epigenetics - Technology Adoption Potential And Development By Geography 7. Epigenetics Competitive Landscape 8. Intellectual Property And Research Strength Analysis 9. Analyst Insights And Recommendations 10. Company Profiles Companies Mentioned: - 4Sc (Germany) - Celgene (U.S.) - Cellcentric (U.K.) - Ch3 Biosystems (U.S.) - Covaris Inc. (U.S.) - Eisai Co. Ltd. (Japan) - Epiontis (Germany) - Epitherapeutics (Denmark) - Epizyme (U.S.) - Karus Therapeutics (U.K.) - Merck Millipore (U.S.) - Ribomed Biotechnologies (U.S.) For more information visit http://www.researchandmarkets.com/research/27...pigenetics
2013 Report on the International Biomarkers Market - Includes Forecasts to 2018
M2 - Thu Dec 19, 4:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/jjq7jz/biomarkers_market) has announced the addition of the "2013 Report on the International Biomarkers Market - Includes Forecasts to 2018" report to their offering. Biomarkers comprise definite cells, genes, molecules, gene products, enzymes, or hormones which are objectively measured as an indicator of typical biological processes, pathogenic processes, or pharmacologic response to a therapeutic intrusion. Major application areas of biomarkers are early disease diagnosis and prevention, drug target recognition, and drug discovery and development. The global market showcases high growth potential in the near future. This market is expected to grow at a CAGR of 18.5% from 2013 to 2018, to reach $40.8 billion by 2018. The key players in this market are Roche Diagnostics Limited (Switzerland), Johnson & Johnson (U.S.), GlaxoSmithKline, Plc. (U.K.), Siemens Healthcare (Germany), Abbott Laboratories, Inc. (U.S.), GE Healthcare (U.K.), Affymetrix, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Epigenomics AG (Germany), Eisai Co. Ltd. (Japan), Bio-Rad Laboratories, Inc. (U.S.), Eli Lilly and Company (U.S.), Merck & Co. (U.S.), Genomic Health, Inc. (U.S.), and Agilent Technologies Inc. (U.S.) Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Biomarkers Market, By Discovery Technologies 5 Services Market Of Biomarkers 6 Biomarkers Application Market 7 Biomarkers Indication Market 8 Geographical Analysis 9 Competitive Landscape 10 Company Profiles Companies Mentioned: - Abbott Laboratories - BGI - Bayer Ag - Bristol-Myers Squibb - Caprion Proteomics Inc - Crescendo Bioscience - Eisai Co Ltd - Epiontis GMBH - Epistem Holdings PLC - Eurogentec SA - Evotec AG - Glaxosmithkline PLC - Ipsen - Johnson & Johnson - Merck & Co - Micromedic Technologies Ltd - Myriad Genetics Inc - Nextgen Sciences Inc - Novartis International AG - Ocimum Biosolutions Ltd - Pacific Biomarkers Inc - Pfizer Inc - Pronota NV - Proteome Sciences Plc - Qiagen Nv - Quintiles Transnational Corporation - Roche Diagnostics Limited - Sanofi-Aventis - Siemens Healthcare - Trans-Hit Biomarkers Inc - Vermillion Inc For more information visit http://www.researchandmarkets.com/research/jj...ers_market
More Work Than Play For Hosts This Holiday Season
PR Newswire - Wed Dec 18, 9:37AM CST
To help ease the pressure for hosts around the world this holiday season, InterContinental Hotels Group (IHG), whose family of brands includes InterContinental® Hotels & Resorts, Crowne Plaza® Hotels & Resorts, Hotel Indigo® hotels, Holiday Inn® hotels, Holiday Inn Resort® hotels, Holiday Inn Club Vacations® hotels, Holiday Inn Express® hotels, Staybridge Suites® hotels and Candlewood Suites® hotels, has tapped into its vast hospitality expertise to create a new interactive, IHG Guide to Hospitality.
Hepatic (Liver) Tumor Global Clinical Trials Review, H2, 2013 Includes an Overview of the Trial Numbers and their Recruitment Status
M2 - Fri Dec 13, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/wz3twf/hepatic_liver) has announced the addition of the "Hepatic (Liver) Tumor Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Hepatic (Liver) Tumor Global Clinical Trials Review, H2, 2013" provides data on the Hepatic (Liver) Tumor clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatic (Liver) Tumor. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatic (Liver) Tumor. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: -Bayer AG -Celsion Corporation -Daiichi Sankyo Company, Limited -Eisai Co., Ltd. -GlaxoSmithKline plc -Instituto Cientifico y Tecnologico de Navarra -Jennerex Biotherapeutics, Inc. -Massachusetts General Hospital -Memorial Sloan Kettering Cancer Center -National Cancer Institute -National Institutes of Health Clinical Center -OXiGENE, Inc. -Sun Yat-sen University -The Techint Group -Tianjin First Central Hospital -Tokyo University of Science -Transgene SA -University of Zurich -Wake Forest University For more information visit http://www.researchandmarkets.com/research/wz...atic_liver About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2013 Report on the International Psoriasis Therapeutics Market - Includes Forecast to 2016
M2 - Mon Dec 09, 4:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/gnjmwj/global_psoriasis) has announced the addition of the "2013 Report on the International Psoriasis Therapeutics Market - Includes Forecast to 2016" report to their offering. The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas, and the EMEA and APAC regions; it also covers the Global Psoriasis Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key questions answered in this report: - What will the market size be in 2016 and what will be the growth rate? - What are key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by key vendors? - What are the strengths and weaknesses of each of these key vendors? You can request one free hour of our analyst's time when you purchase this market report. Details provided within the report. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Types of Psoriasis 7. Market Landscape 8. Geographical Segmentation 9. Rate of Incidence and Prevalence 10. Pipeline Analysis 10.1 Topical Treatment Pipeline Analysis 10.2 Oral Treatment Pipeline Analysis 10.3 Injectable Treatment Pipeline Analysis 11. Vendor Landscape 12. Buying Criteria 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Key Vendor Analysis 19. Other Reports in this Series Companies Mentioned: - Abbvie Inc. - Amgen Inc. - AstraZeneca plc - Bristol Myers Squibb Co. - Celgene Corp. - Eisai Co. Ltd. - Eli Lilly and Co. - GlaxoSmithKline plc - Incyte Corp. - Isotechnika Inc. - Janssen Biotech Inc. - LEO Pharma A/S - Merck & Co. Inc. - Novartis International AG - Pfizer Inc. - UCB S.A For more information visit http://www.researchandmarkets.com/research/gn..._psoriasis
Market Research: Depression - Pipeline Review, H2 2013
M2 - Fri Dec 06, 3:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/q2dd65/depression) has announced the addition of the "Depression - Pipeline Review, H2 2013" report to their offering. 'Depression - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Depression. Scope - A snapshot of the global therapeutic scenario for Depression. - A review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Depression pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH AstraZeneca PLC GlaxoSmithKline plc Daiichi Sankyo Company, Ltd Taisho Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Limited Neurocrine Biosciences, Inc. Aphios Corporation Eisai Co., Ltd. H Lundbeck A/S Mitsubishi Tanabe Pharma Corporation Pfizer Inc. Sigma-Tau S.p.A. Addex Pharmaceuticals FAES Farma SA Anavex Life Sciences Corp. Karo Bio KunWha Pharmaceutical Co., Ltd. Newron Pharmaceuticals S.p.A. M et P Pharma AG Angelini Group Domain Therapeutics For more information visit http://www.researchandmarkets.com/research/q2dd65/depression About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Arterial Thrombosis - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 24, 3:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/f8f4ch/arterial) has announced the addition of the "Arterial Thrombosis - Pipeline Review, H2 2013" report to their offering. 'Arterial Thrombosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Arterial Thrombosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Arterial Thrombosis. Scope - A snapshot of the global therapeutic scenario for Arterial Thrombosis. - A review of the Arterial Thrombosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Arterial Thrombosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Arterial Thrombosis Overview Therapeutics Development Pipeline Products for Arterial Thrombosis - Overview Late Stage Products Clinical Stage Products Early Stage Products Arterial Thrombosis - Products under Development by Companies Arterial Thrombosis - Therapeutics Assessment Drug Profiles ticagrelor - Drug Profile temanogrel hydrochloride - Drug Profile PZ-128 - Drug Profile BMS-593214 - Drug Profile ER-410660 - Drug Profile E-5539 - Drug Profile Arterial Thrombosis - Recent Pipeline Updates Arterial Thrombosis - Dormant Projects Arterial Thrombosis - Product Development Milestones Featured News & Press Releases List of Tables List of Figures Companies Mentioned Bristol-Myers Squibb Company AstraZeneca PLC Eisai Co., Ltd. Arena Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/f8f4ch/arterial About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Advisory: Public Health Agency of Canada
Marketwire - Fri Feb 21, 2:35PM CST
The Honourable Rona Ambrose, Federal Minister of Health, joined by Canadian Tire and LIFT Philanthropy Partners, will announce an important initiative to encourage children and youth and all Canadians to be more active.
Access Midstream Partners Posts Financial Results for the 2013 Fourth Quarter and Full Year
Close-Up Media - Thu Feb 20, 11:31PM CST
Access Midstream Partners, L.P. announced financial results for the 2013 fourth quarter and full year. The Partnership's adjusted EBITDA for the 2013 fourth quarter totaled $240.6 million, an increase of $121.6 million, or 102.2 percent, from 2012 fourth quarter adjusted EBITDA of $119.0 million.
Global Amyotrophic Lateral Sclerosis Market 2014-2018: Advanced New Discoveries and Treatments Sheds Light on Factors Involved In ALS
M2 - Thu Feb 13, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/3qv6rf/global) has announced the addition of the "Global Amyotrophic Lateral Sclerosis Market 2014-2018" report to their offering. The analysts forecast the Global Amyotrophic Lateral Sclerosis Drugs Market to grow at a CAGR of 5.39 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Amyotrophic Lateral Sclerosis Drugs Market has also been witnessing the increasing awareness of ALS drugs. However, the patent expiry of Rilutek could pose a challenge to the growth of this market. Key vendors dominating this space include Covis Pharmaceutical Inc., Eisai Co. Ltd., GlaxoSmithKline plc, and Mitsubishi Tanabe Pharma Corp. Other vendors mentioned in the report are Amorfix Life Sciences Ltd., BrainStrom Cell Therapeutics Inc., Newron Pharmaceuticals S.p.A, Neuraltus Pharmaceuticals Inc., Nutra Pharma Corp., Oxford BioMedica plc, Pharnext SAS, and Q-Therapeutics Inc. Commenting on the report, an analyst from the team said: The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as ALS awareness month. The ALS Association strives to involve and engage patients and families in the process of increasing awareness and advocating for legislative changes. Similarly, CDMRP also organizes the ALS Research Program. The global research effort through this program has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS. According to the report, one of the main drivers in this market is the increase in the aging population. The number of patients suffering from ALS is increasing due to its relatively high prevalence in the elderly population. For more information visit http://www.researchandmarkets.com/research/3qv6rf/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013
M2 - Thu Feb 13, 2:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/dcl2zl/recurrent) has announced the addition of the "Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013" report to their offering. 'Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM). Key Topics Covered: Introduction Recurrent Glioblastoma Multiforme (GBM) Overview Therapeutics Development Clinical Stage Products Early Stage Products Drug Profiles bosutinib - Drug Profile axitinib - Drug Profile onartuzumab - Drug Profile dacomitinib - Drug Profile rindopepimut - Drug Profile VB-111 - Drug Profile ANG-1005 - Drug Profile AT-101 - Drug Profile vorinostat - Drug Profile buparlisib hydrochloride - Drug Profile pazopanib hydrochloride - Drug Profile memantine hydrochloride - Drug Profile galunisertib - Drug Profile G-200 - Drug Profile ERC-1671 - Drug Profile lenvatinib - Drug Profile trebananib - Drug Profile TB-403 - Drug Profile nabiximols - Drug Profile golvatinib - Drug Profile ARC-100 - Drug Profile New Castle Disease Virus - HUJ Oncolytic Virus - Drug Profile vocimagene amiretrorepvec flucytosine ER - Drug Profile golvatinib lenvatinib - Drug Profile ICT-121 - Drug Profile BTSC mRNA Loaded Dendritic Cell Vaccine - Drug Profile AZD-7451 - Drug Profile DNX-2401 - Drug Profile OS-2966 - Drug Profile Recurrent Glioblastoma Multiforme (GBM) - Recent Pipeline Updates Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects Recurrent Glioblastoma Multiforme (GBM) - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned F. Hoffmann-La Roche Ltd. Amgen Inc. AstraZeneca PLC Eli Lilly and Company GlaxoSmithKline plc Agenus, Inc. Merck & Co., Inc. Novartis AG Eisai Co., Ltd. Pfizer Inc. GW Pharmaceuticals plc Celldex Therapeutics, Inc. ImmunoCellular Therapeutics, Ltd. ThromboGenics NV AngioChem Inc. Ascenta Therapeutics, Inc. Vascular Biogenics Ltd. Archer Biosciences, Inc Tocagen Inc. DNAtrix, Inc. ERC Belgium SA OncoSynergy Inc For more information visit http://www.researchandmarkets.com/research/dcl2zl/recurrent About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Eisai Announces Launch of Pariet(R) Triple Formulation Combination Packs Rabecure(R) 400 and 800 and Rabefine(R), for Primary and Secondary H.Pyloei Eradication Respectively, in Japan
JCN Newswire - Wed Feb 12, 11:09PM CST
Eisai Co., Ltd. announced today that it will launch two types of triple formulation combination packs that contain its proton pump inhibitor Pariet(R) (rabeprazole sodium) in Japan on February 14 for use in Helicobacter pylori eradication.
Eisai Announces Launch of Vascular Embolization Device DC Bead(R) in Japan
JCN Newswire - Mon Feb 03, 1:19AM CST
Eisai Co., Ltd. announced today that it will launch the vascular embolization device DC Bead(R) (specially controlled medical device) in Japan on February 4.
Phase III Trial Shows Lenvatinib Meets Primary Endpoint of Progression Free Survival Benefit in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
JCN Newswire - Mon Feb 03, 1:18AM CST
Eisai Co., Ltd. announced today that the Phase III SELECT trial (Study 303) of lenvatinib, an investigational selective tyrosine kinase inhibitor (TKI) with a novel binding mode, the first-in-class of its kind, met its primary endpoint. Compared to placebo, lenvatinib showed a highly statistically significant improvement in progression free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC).
Latest Thyroid Cancer Pipeline Review
M2 - Tue Jan 28, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/zmc3df/thyroid_cancer) has announced the addition of the "Thyroid Cancer - Pipeline Review, H2 2013" report to their offering. 'Thyroid Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer. Scope - A snapshot of the global therapeutic scenario for Thyroid Cancer. - A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Thyroid Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Bio-Path Holdings, Inc. - Eisai Co., Ltd. - Bayer AG - Bionomics Limited - Azaya Therapeutics Incorporated - Vascular Biogenics Ltd. - Biovista Inc. - Trophogen, Inc. - centrose llc - Ecrins Therapeutics SAS For more information visit http://www.researchandmarkets.com/research/zm...oid_cancer
Fashion - How to Wear Leggings
by Shifa Mwesigye - All Africa Global Media - Tue Jan 21, 11:31PM CST
Ladies, legging are not pants, they should not be won with a tank top, however well your behind may be rounded. Even if you have the perfect hour-glass figure, you have to cover it up - I mean the butt.
Venous Thromboembolism Global Clinical Trials Review, H2 2013 Report
M2 - Fri Jan 17, 9:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/t9vr95/venous) has announced the addition of the "Venous Thromboembolism Global Clinical Trials Review, H2, 2013" report to their offering. Venous Thromboembolism Global Clinical Trials Review, H2, 2013 provides data on the Venous Thromboembolism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Venous Thromboembolism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Venous Thromboembolism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Venous Thromboembolism Therapeutics Clinical Trials - Bayer AG - Sanofi - GlaxoSmithKline plc - C. H. Boehringer Sohn AG & Co. KG - Astellas Pharma Inc. - Daiichi Sankyo Company, Limited - Pfizer Inc. - AstraZeneca PLC - Bristol-Myers Squibb Company - Eisai Co., Ltd. Clinical Trial Overview of Top Institutes / Government - National Heart, Lung, and Blood Institute - Hamilton Health Sciences - Ottawa Hospital Research Institute - Brigham and Women's Hospital - McMaster University - Centre Hospitalier Universitaire de Saint Etienne - Universita di Padova - Mayo Clinic - Universita degli Studi dell'Insubria - The Utrecht Institute for Pharmaceutical Sciences For more information visit http://www.researchandmarkets.com/research/t9vr95/venous
MCB Bank Selects Oracle WebLogic Suite 12c to Support Its Core Banking Upgrade to Power Exceptional Experiences for Employees and Customers
M2 - Thu Jan 16, 9:29AM CST
News Summary
Sezary Syndrome Global Clinical Trials Review, H2 2013 - Features Players such as Merck & Co., Inc. and Shionogi & Co., Ltd.
M2 - Fri Jan 10, 3:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/l3xgrw/sezary_syndrome) has announced the addition of the "Sezary Syndrome Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Sezary Syndrome Global Clinical Trials Review, H2, 2013" provides data on the Sezary Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sezary Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sezary Syndrome. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: -Angimmune LLC -Eisai Co., Ltd. -Emergent BioSolutions Inc. -Janssen Global Services, LLC -Kirin Holdings Company, Limited -Merck & Co., Inc. -National Cancer Institute -Northwestern University -OncoSec Medical Inc. -Roswell Park Cancer Institute -Shionogi & Co., Ltd. -Spectrum Pharmaceuticals, Inc. -Stanford University -University of Washington -Wake Forest University For more information visit http://www.researchandmarkets.com/research/l3...y_syndrome About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Pharmerging Market Report - Forecasts to 2016
M2 - Thu Jan 09, 10:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/w9jhsf/pharmerging) has announced the addition of the "Global Pharmerging Market Report - Forecasts to 2016" report to their offering. One of the major drivers in this market is the increased healthcare spending. It was estimated that Pharmerging markets constitute about 20 percent of pharmaceutical spending and are expected to contribute 30 percent by 2016 of the Global Pharmaceutical market spending. Partnership activities with vendors toward the development of new products especially generic drugs are increasingly being adopted by big pharmaceutical companies to sustain their presence in the Pharmerging markets. For example, Pfizer Inc. announced a partnership with Laborat?rio Teuto Brasileiro SA to develop and commercialize generic medicines in 2010. Another example includes Eli Lilly which expanded a strategic partnership with Chinese manufacturer Novast Laboratories Ltd. in 2011 to serve Chinese patients with high-quality generic medicines. Such partnership activities are expected to grow during the forecast period, boosting the Pharmerging markets. Further, the report states that one of the challenges in this market is the price pressure faced by the big pharmaceutical companies. Governments in the Pharmerging markets have developed policies that favor the local manufacturers. In order to market their products big pharmaceutical companies are forced to reduce their product prices to attract the local populace and government. The key vendors dominating this market space are: - Abbott Laboratories - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca plc. - Bayer HealthCare AG. - Boehringer Ingelheim Pharmaceuticals Corp. - Bristol-Myers Squibb Co. - Eisai Co Ltd. - GlaxoSmithKline plc - Johnson & Johnson - Eli Lilly and Co. - Merck & Co Inc. Novartis International AG. - Novo Nordisk A/S. - Pfizer Inc. - Roche Holding Ltd. - Sanofi S.A. Key Topics Covered: 01. Executive Summary 02. Scope of the Report 03. Market Research Methodology 04. List of Abbreviations 05. Introduction 06. Market Landscape 07. Market Segmentation by Geographical Regions 08. Market Overview of Tier 1 Countries 09. Market Overview of Tier 2 Countries 10. Tier 3 Countries 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/w9...harmerging
2013 Report on the International Epigenetics Technology Market - World Forecasts to 2017
M2 - Mon Jan 06, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/27bx7t/epigenetics) has announced the addition of the "2013 Report on the International Epigenetics Technology Market - World Forecasts to 2017" report to their offering. This technology report categorizes the market for epigenetics by geographical region (including the important countries in each region), applications, and epigenetic mechanisms, forecasting the market value in revenue by analyzing the current and future trends in research, diagnostics and therapeutics industries. A detailed description of the global technology developments and evolving trends in the epigenetics field with key prominence on research innovations, collaborative efforts and focused research through consortiums dedicated for epigenetics. A close view on the drug development for treatment of various diseases by providing the details and status of current epigenetic drugs in pipeline. An impact analysis of major drivers, restraints and challenges influencing the adoption and growth of epigenetics market during the period from 2012 to 2017. Market size - Global market forecast for 2012-2017, including demand side analysis and strategic recommendations for technology/product developers. Competitive landscape based on the analysis of key patents and research publications that gives an insight into prominent activities and global participants. Key Topics Covered: 1. Introduction 2. Executive Summary 3. Epigenetics - Technology Landscape Analysis 4. Epigenetics - Market Landscape Analysis 5. Technology Investment Potential 6. Epigenetics - Technology Adoption Potential And Development By Geography 7. Epigenetics Competitive Landscape 8. Intellectual Property And Research Strength Analysis 9. Analyst Insights And Recommendations 10. Company Profiles Companies Mentioned: - 4Sc (Germany) - Celgene (U.S.) - Cellcentric (U.K.) - Ch3 Biosystems (U.S.) - Covaris Inc. (U.S.) - Eisai Co. Ltd. (Japan) - Epiontis (Germany) - Epitherapeutics (Denmark) - Epizyme (U.S.) - Karus Therapeutics (U.K.) - Merck Millipore (U.S.) - Ribomed Biotechnologies (U.S.) For more information visit http://www.researchandmarkets.com/research/27...pigenetics
2013 Report on the International Biomarkers Market - Includes Forecasts to 2018
M2 - Thu Dec 19, 4:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/jjq7jz/biomarkers_market) has announced the addition of the "2013 Report on the International Biomarkers Market - Includes Forecasts to 2018" report to their offering. Biomarkers comprise definite cells, genes, molecules, gene products, enzymes, or hormones which are objectively measured as an indicator of typical biological processes, pathogenic processes, or pharmacologic response to a therapeutic intrusion. Major application areas of biomarkers are early disease diagnosis and prevention, drug target recognition, and drug discovery and development. The global market showcases high growth potential in the near future. This market is expected to grow at a CAGR of 18.5% from 2013 to 2018, to reach $40.8 billion by 2018. The key players in this market are Roche Diagnostics Limited (Switzerland), Johnson & Johnson (U.S.), GlaxoSmithKline, Plc. (U.K.), Siemens Healthcare (Germany), Abbott Laboratories, Inc. (U.S.), GE Healthcare (U.K.), Affymetrix, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Epigenomics AG (Germany), Eisai Co. Ltd. (Japan), Bio-Rad Laboratories, Inc. (U.S.), Eli Lilly and Company (U.S.), Merck & Co. (U.S.), Genomic Health, Inc. (U.S.), and Agilent Technologies Inc. (U.S.) Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Biomarkers Market, By Discovery Technologies 5 Services Market Of Biomarkers 6 Biomarkers Application Market 7 Biomarkers Indication Market 8 Geographical Analysis 9 Competitive Landscape 10 Company Profiles Companies Mentioned: - Abbott Laboratories - BGI - Bayer Ag - Bristol-Myers Squibb - Caprion Proteomics Inc - Crescendo Bioscience - Eisai Co Ltd - Epiontis GMBH - Epistem Holdings PLC - Eurogentec SA - Evotec AG - Glaxosmithkline PLC - Ipsen - Johnson & Johnson - Merck & Co - Micromedic Technologies Ltd - Myriad Genetics Inc - Nextgen Sciences Inc - Novartis International AG - Ocimum Biosolutions Ltd - Pacific Biomarkers Inc - Pfizer Inc - Pronota NV - Proteome Sciences Plc - Qiagen Nv - Quintiles Transnational Corporation - Roche Diagnostics Limited - Sanofi-Aventis - Siemens Healthcare - Trans-Hit Biomarkers Inc - Vermillion Inc For more information visit http://www.researchandmarkets.com/research/jj...ers_market
More Work Than Play For Hosts This Holiday Season
PR Newswire - Wed Dec 18, 9:37AM CST
To help ease the pressure for hosts around the world this holiday season, InterContinental Hotels Group (IHG), whose family of brands includes InterContinental® Hotels & Resorts, Crowne Plaza® Hotels & Resorts, Hotel Indigo® hotels, Holiday Inn® hotels, Holiday Inn Resort® hotels, Holiday Inn Club Vacations® hotels, Holiday Inn Express® hotels, Staybridge Suites® hotels and Candlewood Suites® hotels, has tapped into its vast hospitality expertise to create a new interactive, IHG Guide to Hospitality.
Hepatic (Liver) Tumor Global Clinical Trials Review, H2, 2013 Includes an Overview of the Trial Numbers and their Recruitment Status
M2 - Fri Dec 13, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/wz3twf/hepatic_liver) has announced the addition of the "Hepatic (Liver) Tumor Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Hepatic (Liver) Tumor Global Clinical Trials Review, H2, 2013" provides data on the Hepatic (Liver) Tumor clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatic (Liver) Tumor. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatic (Liver) Tumor. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: -Bayer AG -Celsion Corporation -Daiichi Sankyo Company, Limited -Eisai Co., Ltd. -GlaxoSmithKline plc -Instituto Cientifico y Tecnologico de Navarra -Jennerex Biotherapeutics, Inc. -Massachusetts General Hospital -Memorial Sloan Kettering Cancer Center -National Cancer Institute -National Institutes of Health Clinical Center -OXiGENE, Inc. -Sun Yat-sen University -The Techint Group -Tianjin First Central Hospital -Tokyo University of Science -Transgene SA -University of Zurich -Wake Forest University For more information visit http://www.researchandmarkets.com/research/wz...atic_liver About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2013 Report on the International Psoriasis Therapeutics Market - Includes Forecast to 2016
M2 - Mon Dec 09, 4:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/gnjmwj/global_psoriasis) has announced the addition of the "2013 Report on the International Psoriasis Therapeutics Market - Includes Forecast to 2016" report to their offering. The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas, and the EMEA and APAC regions; it also covers the Global Psoriasis Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key questions answered in this report: - What will the market size be in 2016 and what will be the growth rate? - What are key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by key vendors? - What are the strengths and weaknesses of each of these key vendors? You can request one free hour of our analyst's time when you purchase this market report. Details provided within the report. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Types of Psoriasis 7. Market Landscape 8. Geographical Segmentation 9. Rate of Incidence and Prevalence 10. Pipeline Analysis 10.1 Topical Treatment Pipeline Analysis 10.2 Oral Treatment Pipeline Analysis 10.3 Injectable Treatment Pipeline Analysis 11. Vendor Landscape 12. Buying Criteria 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Key Vendor Analysis 19. Other Reports in this Series Companies Mentioned: - Abbvie Inc. - Amgen Inc. - AstraZeneca plc - Bristol Myers Squibb Co. - Celgene Corp. - Eisai Co. Ltd. - Eli Lilly and Co. - GlaxoSmithKline plc - Incyte Corp. - Isotechnika Inc. - Janssen Biotech Inc. - LEO Pharma A/S - Merck & Co. Inc. - Novartis International AG - Pfizer Inc. - UCB S.A For more information visit http://www.researchandmarkets.com/research/gn..._psoriasis
Market Research: Depression - Pipeline Review, H2 2013
M2 - Fri Dec 06, 3:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/q2dd65/depression) has announced the addition of the "Depression - Pipeline Review, H2 2013" report to their offering. 'Depression - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Depression. Scope - A snapshot of the global therapeutic scenario for Depression. - A review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Depression pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH AstraZeneca PLC GlaxoSmithKline plc Daiichi Sankyo Company, Ltd Taisho Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Limited Neurocrine Biosciences, Inc. Aphios Corporation Eisai Co., Ltd. H Lundbeck A/S Mitsubishi Tanabe Pharma Corporation Pfizer Inc. Sigma-Tau S.p.A. Addex Pharmaceuticals FAES Farma SA Anavex Life Sciences Corp. Karo Bio KunWha Pharmaceutical Co., Ltd. Newron Pharmaceuticals S.p.A. M et P Pharma AG Angelini Group Domain Therapeutics For more information visit http://www.researchandmarkets.com/research/q2dd65/depression About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
